Influence of histological subtypes on the risk of an invasive recurrence in a large series of stage I borderline ovarian tumor including 191 conservative treatments

Annals of Oncology

Volumn 25, Issue 7, 2014, Pages 1312-1319

  Uzan, C ^a,b   Nikpayam, M ^a   Ribassin Majed, L ^a   Gouy, S ^a   Bendifallah, S ^c,d,e   Cortez, A ^c   Rey, A ^a   Duvillard, P ^a   Darai, E ^c,d,e   Morice, Philippe ^a,b,f  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c HÔPITAL TENON   (France)

^d CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Borderline ovarian tumors; Invasive; Mucinous; Prognostic factors; Recurrence; Serous

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CHILD; FEMALE; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MUCINOUS BORDERLINE OVARIAN TUMOR; OVARIECTOMY; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY; SEROUS BORDERLINE OVARIAN TUMOR; MIDDLE AGED; OVARIAN NEOPLASMS; PATHOLOGY; RECURRENT DISEASE; TUMOR INVASION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; RECURRENCE; YOUNG ADULT;

EID: 84903748378     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu139     Document Type: Article

References (20)

1. Trimble CL, Kosary C, Trimble EL. Long-term survival and patterns of care in women with ovarian carcinoma: a population-based analysis. Gynecol Oncol 2002; 86: 34-37.
2. Morice P, Uzan C, Fauvet R et al. Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. Lancet Oncol 2012; 13: e103-e115.
3. Daraï E, Fauvet R, Uzan C et al. Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options. Hum Reprod Update 2013; 19: 151-166.
4. Longacre TA, McKenney JK, Tazelaar HD et al. Ovarian serous tumors of low malignant potential (borderline tumors. Outcome-based study of 276 patients with long-term (> 5-year) follow up. Am J Surg Pathol 2005; 29: 707-723.
5. Koskas M, Uzan C, Gouy S et al. Prognostic factors of a large retrospective series of mucinous borderline tumors of the ovary (excluding peritoneal pseudomyxoma). Ann Surg Oncol 2011; 18(1):40-48.
6. Benito V, Lubrano A, Arencibia O et al. Serous and mucinous borderline ovarian tumors: are there real differences between these two entities? Eur J Obstet Gynecol Reprod Biol 2010; 153: 188-192.
7. Du Bois A, Ewald-Riegler N, de Gregorio N et al. Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group. Borderline tumours of the ovary: a cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group. Eur J Cancer 2013; 49: 1905-1914.
8. Tavassoli FA, Devilee P. World Health Organization. Classification of the Tumours. Pathology and Genetics. Tumours of the Breast and Female Genital Organs. Lyon:IARC Press 2003.
9. Seidman JD, Kurman RJ. Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol 1996; 20: 1331-1345.
10. Zanetta G, Rota S, Chiari S et al. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol 2001; 19: 2656-2664.
11. Khunamornpong S, Settakorn J, Sukpan K et al. Mucinous tumor of low malignant potential ("borderline" or "atypical proliferative" tumor) of the ovary: a study of 171 cases with the assessment of intraepithelial carcinoma and microinvasion. Int J Gynecol Pathol 2011; 30: 218-230.
12. Guvenal T, Dursun P, Hasdemir PS et al. Effect of surgical staging on 539 patients with borderline ovarian tumors: a Turkish Gynecologic Oncology Group study. Gynecol Oncol 2013; 131: 546-550.
13. Kokawa K, Mikami Y, Sakata H et al. Clinical outcome and prognostic factors in borderline tumors of the ovary. Results from 17 years' experience in the Kinki District of Japan (1990-2006). Eur J Gynaecol Oncol 2009; 30: 155-161.
14. Park J-Y, Kim D-Y, Kim J-H et al. Surgical management of borderline ovarian tumors: the role of fertility-sparing surgery. Gynecol Oncol 2009; 113: 75-82.
15. Wong HF, Low JJ, Chua Y et al. Ovarian tumors of borderline malignancy: a review of 247 patients from 1991 to 2004. Int J Gynecol Cancer 2007; 17: 342-349.
16. Silverberg SG, Bell DA, Kurman RJ et al. Borderline ovarian tumors: key points and workshop summary. Hum Pathol 2004; 35: 910-917.
17. Siriaunkgul S, Robbins KM, McGowan L et al. Ovarian mucinous tumors of low malignant potential: a clinicopathologic study of 54 tumors of intestinal and müllerian type. Int J Gynecol Pathol 1995; 14: 198-208.
18. Lee KR, Scully RE. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'. Am J Surg Pathol 2000; 24: 1447-1464.
19. Yokoyama Y, Moriya T, Takano T et al. Clinical outcome and risk factors for recurrence in borderline ovarian tumours. Br J Cancer 2006; 94: 1586-1591.
20. Song T, Lee Y-Y, Choi CH et al. Prognosis in patients with serous and mucinous stage I borderline ovarian tumors. Int J Gynecol Cancer 2012; 22: 770-777.